Click here to visit Original posting
The Food and Drug Administration finally gave 23andMe a long sought-after green light today to sell genetic tests and their accompanying health risk reports to consumers for up to ten diseases, including late onset Alzheimers and Parkinson’s.
In November 2013, the FDA put a moratorium on 23andMe’s ability to provide any health information associated with its personal genome testing. Read More